Tag: Clinuvel Pharmaceuticals Limited

MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide ...

 ASX: XETRA-DAX:  Level 1 ADR:CUV UR9 CLVLY  EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five patientsbrain scans (MRI-FLAIR2) in all patients ...

LONDON, April 29, 2022 (GLOBE NEWSWIRE) --       Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share ...

MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic hormone (ACTH). The Company has secured supply ...